Login to Your Account



Crucell Regains Cell Culture Flu Vaccine Program from Sanofi

By Cormac Sheridan


Wednesday, July 14, 2010
In a quid pro quo with erstwhile partner Sanofi Pasteur, Crucell NV regained control over its cell-culture-based influenza vaccine program by agreeing not to exercise its rights, under a change-of-control clause, to terminate a contract with Sanofi Pasteur subsidiary Shantha Biotechnics Ltd. on the production of a pediatric vaccine against Haemophilus influenzae B. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription